Updated
Starling OncologySTLN · Healthcare
$4.54+4.61%
Market cap$463M
IndustryMedical Care Facilities
Starling Oncology (STLN) Revenue breakdown
By segment, Specialty pharmacy is the largest at 54% of fiscal 2025 revenue, growing 33% a year over 5 years.
Summary
By product, Specialty pharmacy is the largest at 54% of fiscal 2025 revenue, growing 33% a year over 5 years.
Follow STLNResults, insider buys and big moves by email
Revenue by segment
Fiscal years, as Starling Oncology reports them in its 10-K filings; fiscal 2025 total $503M.
| Segments | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| Specialty pharmacy | $64M | $73M | $79M | $104M | $180M | $269M | 54% |
| Patient services | $117M | $124M | $167M | $214M | $205M | $229M | 46% |
| Clinical trials & other | $7M | $6M | $6M | $7M | $9M | $5M | 1% |
Revenue by product
Fiscal years, as Starling Oncology reports them in its 10-K filings; fiscal 2025 total $503M.
| Products | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| Specialty pharmacy | $64M | $73M | $79M | $104M | $180M | $269M | 54% |
| FFS revenue | $79M | $70M | $105M | $143M | $136M | $149M | 30% |
| Capitated revenue | $37M | $54M | $61M | $70M | $69M | $80M | 16% |
| Clinical trials & other | $7M | $6M | $6M | $7M | $9M | $5M | 1% |
Questions about Starling Oncology
Where does Starling Oncology make its money?
In fiscal 2025, by segment: Specialty pharmacy $269M, Patient services $229M, Clinical trials & other $5M.
From Starling Oncology's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.
Starling OncologySTLN